Life Science Contract Research Organisation (CRO)
2008 - 2018
Abzena offers product specific licences and services for the application of conjugation and polymer technologies to enable the development of better biopharmaceuticals through its wholly owned subsidiaries Polytherics and Antitope.
How did we help?
We were originally the lead investor in Warwick Effect Polymers Limited, which PolyTherics Limited acquired in 2012. Polytherics later acquired Antitope and rebranded as Abzena in 2014.
Abzena was successfully floated on the London AIM market in summer 2014, and was ultimately bought in summer 2018 by WCAS, a global healthcare-focused private equity house.